RxDoctor Payments Data

Laura Archuleta, MD

Family Medicine · Mandan, NDNPI 1245284314

Payments from drug & device makers

$575in general payments, 2019–2025

Across 18 payments — averaging $31.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$142
  • Abbott$136
  • Nevro Corp.$115
  • Astellas Pharma US Inc$35
  • Phathom Pharmaceuticals, Inc.$31
  • AbbVie$31
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$575 in reported general payments places this provider in the 75th percentile of 337 family medicine providers in North Dakota.

See all family medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$218,345
Medicare patients
416
Services billed
9,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$70,884
TrulicityDulaglutide49$48,563
OzempicSemaglutide38$41,426
XareltoRivaroxaban33$28,287
JardianceEmpagliflozin28$26,496
JanuviaSitagliptin Phosphate30$16,658
Bydureon BciseExenatide Microspheres13$13,788
MounjaroTirzepatide11$10,972
Tresiba Flextouch U-100Insulin Degludec11$9,578
LinzessLinaclotide13$7,727
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$6,829
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$6,587
Advair HfaFluticasone Propion/Salmeterol11$5,027
Levothyroxine Sodium281$4,638
Breo ElliptaFluticasone/Vilanterol11$4,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$14$59,53460 claims
AbbVieLinzess$31$7,72713 claims
GSKBreo Ellipta$13$4,51011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 337 family medicine providers in North Dakota.

Other family medicine in Mandan

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →